175 related articles for article (PubMed ID: 38823901)
1. Quality control, safety assessment and preparation approaches of low molecular weight heparin.
Yu Y; Song Y; Zhao Y; Wang N; Wei B; Linhardt RJ; Dordick JS; Zhang F; Wang H
Carbohydr Polym; 2024 Sep; 339():122216. PubMed ID: 38823901
[TBL] [Abstract][Full Text] [Related]
2. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis].
Shen Y; Kang J
Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122
[TBL] [Abstract][Full Text] [Related]
3. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
4. Fragment profiling of low molecular weight heparins using reversed phase ion pair liquid chromatography-electrospray mass spectrometry.
Xu X; Li D; Chi L; Du X; Bai X; Chi L
Carbohydr Res; 2015 Apr; 407():26-33. PubMed ID: 25701653
[TBL] [Abstract][Full Text] [Related]
5. Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin.
Yu Y; Fu L; He P; Xia K; Varghese S; Wang H; Zhang F; Dordick J; Linhardt RJ
ACS Chem Biol; 2022 Mar; 17(3):637-646. PubMed ID: 35201757
[TBL] [Abstract][Full Text] [Related]
6. Antithrombin III-Binding Site Analysis of Low-Molecular-Weight Heparin Fractions.
Chen Y; Zhao J; Yu Y; Liu X; Lin L; Zhang F; Linhardt RJ
J Pharm Sci; 2018 May; 107(5):1290-1295. PubMed ID: 29339133
[TBL] [Abstract][Full Text] [Related]
7. De novo synthesis of a narrow size distribution low-molecular-weight heparin.
Chandarajoti K; Xu Y; Sparkenbaugh E; Key NS; Pawlinski R; Liu J
Glycobiology; 2014 May; 24(5):476-86. PubMed ID: 24626379
[TBL] [Abstract][Full Text] [Related]
8. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Jones LE
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD001100. PubMed ID: 28182249
[TBL] [Abstract][Full Text] [Related]
9. Preparation of low molecular weight heparin using an ultrasound-assisted Fenton-system.
Zhi Z; Li J; Chen J; Li S; Cheng H; Liu D; Ye X; Linhardt RJ; Chen S
Ultrason Sonochem; 2019 Apr; 52():184-192. PubMed ID: 30559077
[TBL] [Abstract][Full Text] [Related]
10. Production and chemical processing of low molecular weight heparins.
Linhardt RJ; Gunay NS
Semin Thromb Hemost; 1999; 25 Suppl 3():5-16. PubMed ID: 10549711
[TBL] [Abstract][Full Text] [Related]
11. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase.
Yu Y; Fu L; He P; Xia K; Varghese S; Dordick J; Wang H; Zhang F; Linhardt RJ
Carbohydr Polym; 2022 Nov; 295():119825. PubMed ID: 35988993
[TBL] [Abstract][Full Text] [Related]
13. Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review.
Yan Y; Ji Y; Su N; Mei X; Wang Y; Du S; Zhu W; Zhang C; Lu Y; Xing XH
Carbohydr Polym; 2017 Mar; 160():71-81. PubMed ID: 28115102
[TBL] [Abstract][Full Text] [Related]
14. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy.
Béguin S; Welzel D; Al Dieri R; Hemker HC
Haemostasis; 1999; 29(2-3):170-8. PubMed ID: 10629396
[TBL] [Abstract][Full Text] [Related]
15. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
16. Variability of heparins and heterogeneity of low molecular weight heparins.
Bianchini P; Liverani L; Spelta F; Mascellani G; Parma B
Semin Thromb Hemost; 2007 Jul; 33(5):496-502. PubMed ID: 17629846
[TBL] [Abstract][Full Text] [Related]
17. The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
Mousa SA
Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
Mousa SA
Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
Heaton D; Pearce M
Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
